SRR8518130
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- MYC_TARGETS_V1+0.350
- SPERMATOGENESIS+0.350
- MYC_TARGETS_V2+0.280
- G2M_CHECKPOINT+0.240
- OXIDATIVE_PHOSPHORYLATION+0.210
- DNA_REPAIR+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.130
- PANCREAS_BETA_CELLS+0.100
- PEROXISOME+0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- TNFA_SIGNALING_VIA_NFKB-0.470
- TGF_BETA_SIGNALING-0.450
- ANGIOGENESIS-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- UV_RESPONSE_DN-0.420
- APOPTOSIS-0.390
- COMPLEMENT-0.390
- KRAS_SIGNALING_UP-0.370
- IL2_STAT5_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A85H-01A-11R-A352-07 | — | — | 0.903 |
| 2 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.900 |
| 3 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.897 |
| 4 | ERR2208947 | — | — | 0.896 |
| 5 | SRR5088911 | — | — | 0.894 |
| 6 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.893 |
| 7 | MNG81 | — | — | 0.890 |
| 8 | SAMN03290897 | — | — | 0.890 |
| 9 | 24975492-6b9f-445b-9f6b-daee2f8363d3 | — | — | 0.889 |
| 10 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |